A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors BioNTech
- 29 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Feb 2023 Planned End Date changed from 5 Apr 2024 to 1 Aug 2023.
- 13 Feb 2023 Planned primary completion date changed from 5 Apr 2024 to 1 Aug 2023.